A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(20 sites)

United States

Carolinas HealthCare System Neurosciences Institute - Neurology, Charlotte, North Carolina

Neurology Rare Disease Center, Denton, Texas

University of Virginia, Charlottesville, Virginia

Belgium

UZ Gent, Ghent

Canada

Childrens Hospital of Eastern Ontario, Ottawa